Sun says it didn't run up Ranbaxy shares before deal; FDA approves label update for Teva's Synribo;

@FiercePharma: Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too. More | Follow @FiercePharma

@TracyStaton: Forest founder, CEO set for $100M-plus yield from Actavis buyout. Article | Follow @TracyStaton

@EricPFierce: With all of the deals going on, Teva CEO thinks a buy in biosimilars might be a move it would make. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Positive H7N9 data could help Novartis hawk flu vax business. Article | Follow @CarlyHFierce

> India's Sun Pharma says its Silverstreet Developers unit had no role to play in the run-up of Ranbaxy shares before Sun's deal announcement for the troubled generics maker. Story

> Novartis' ($NVS) Signifor showed superior efficacy in acromegaly patients not controlled on first-generation somatostatin analogues. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> Former Forest Laboratories ($FRX) SVP and general counsel has joined Lowenstein Sandler's life sciences practice. Release

> A soldier claimed Pfizer's ($PFE) anti-smoking drug Chantix drove him to commit murder. More

> Biocon, which makes a scorpion anti-venom drug, has received an FDA warning letter for a plant in Mexico City. More

> Italy is leading an international effort to catch a criminal drug-theft ring. More

> Indian drugmaker Cipla says essential drugs should not be sold under "monopoly." More

> Sanofi ($SNY) says the World Health Organization (WHO) has approved its Shan5 vaccine for purchase from UN agencies. Release

Medical Device News

@FierceMedDev: BioFire Diagnostics wins FDA clearance for innovative GI panel. Article | Follow @FierceMedDev

@VarunSaxena2: Apple on medical tech hiring spree, a possible hint of iWatch plans. Story via Reuters | Follow @VarunSaxena2

@EmilyWFierce: New Dx machine from student at MIT uses magnets and lasers to quickly spot. More from the Boston Globe | Follow @EmilyWFierce

@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Story via FierceDrugDelivery | Follow @MichaelGFierce

> Hospira recalls infusion pump docking station. Piece

> Alere shakes up boardroom, embarks on strategic review. More

> Volcano ticks up sales in Q2 as losses widen. News

Biotech News

@FierceBiotech: Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO. Story | Follow @FierceBiotech

@JohnCFierce: Pfizer down more than 2% on some miserable Q1 numbers. Only more fuel for the M&A fire. | Follow @JohnCFierce

@DamianFierce: It's FDA decision day for epanova, the cardio drug AstraZeneca picked up in its $443M deal for Omthera. | Follow @DamianFierce

@EmilyMFierce: As MERS arrives in U.S., Novavax, UofMaryland report positive preclinical results for MERS vaccine. Story via FierceBiotech Research | Follow @EmilyMFierce

> Global R&D centers brace for another blow as Pfizer circles AstraZeneca. More

> Novartis' long-acting Signifor passes PhIII test for acromegaly. Story

> Regeneron jumps into next-gen gene therapy tech with $640M eye drug deal. Article

CRO News

> Covance slips after narrowing its 2014 ambitions. Article

> Charles River ticks up revenue M&A on tap. More

> Quintiles keeps rolling with another $1B quarter. Report

> Parexel boosts revenue with eyes on a $1.9B year. Article

> Icon cranks up its 2014 expectations after another leap. Story

Biotech IT News

> Bina, SAS and others pitch new tools to boost biopharma R&D. Article

> Novartis steps up MS digital presence with iPhone app. Item

> Buzz: Google Ventures leading $100M round in oncology Big Data platform. More

> Canada to set up cancer cloud computing facility. News

> Medidata unveils Sanofi deal as it looks to recover from rocky April. Story

And Finally... Do statins change our eating habits? More (sub. req.)